BioCentury
ARTICLE | Clinical News

Celyad slides on Phase III heart failure miss

June 29, 2016 1:43 AM UTC

Celyad S.A. (Euronext:CYAD; NASDAQ:CYAD) said cell therapy C-Cure missed the primary endpoint in the Phase III CHART-1 study to treat ischemic heart failure. The company sank EUR 15.95 (40%) to EUR 23.52 in Europe and $14.45 (34%) to $28 on NASDAQ after reporting the news.

The 271-patient study's primary endpoint was a composite of mortality, worsening heart failure events, quality of life, six-minute walk test (6MWT) and left ventricular structure and function at nine months post-procedure. Celyad said there was a "positive trend" on the endpoint, but it was not significant. ...